Long Arg3 IGF-1 analog – Kodiac biolabs

Plain-language summaryIntrigue 65 / 100

IGF-1 LR3 is a long-acting modified form of insulin-like growth factor 1. The R3 modification reduces binding to IGF-binding proteins, extending the half-life from minutes to hours. Used in research contexts for muscle growth studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

43/100

Useful IGF-1R probe with extended half-life but limited novelty and a thin clinical evidence base

Look, IGF-1 LR3 earns its place in a serious lab not because it’s exciting right now, but because it’s the cleanest available probe for IGF-1 receptor biology when extended bioavailability is the requirement. The core engineering is tidy: a 13-residue N-terminal extension combined with Glu-to-Arg substitution at position 3 substantially reduces binding to IGF binding proteins, pushing plasma half-life from roughly 12-15 hours for native IGF-1 to 20-30 hours for LR3. For cell culture work, that extended window matters practically. For in vivo rodent studies, you get more stable receptor occupancy without the dosing burden native IGF-1 imposes. GroPep originally developed it for mammalian cell growth media in the 1990s and that lineage is visible in how it behaves.

That said, the mechanism isnt novel by any stretch. IGF-1R signals through canonical PI3K/Akt/mTOR, and that territory is well-saturated in the literature. We’re not learning anything structurally new about IGF-1 biology by using LR3 that couldn’t be learned with native IGF-1 and careful protocol design. The value here is entirely pharmacokinetic convenience, not mechanistic novelty. The IGFBP-reduction strategy was a real innovation when it was first proposed; in 2026, it’s standard receptor pharmacology.

Where things get complicated is the translational picture. The IGF-1 axis is genuinely important in growth disorders, sarcopenia, and metabolic biology, and theres legitimate investigator interest in how IGF-1 modulation affects muscle protein synthesis and anabolic signaling in aging models. But the clinical base for LR3 specifically is thin. Mecasermin (native IGF-1) has formal regulatory data in severe primary IGF-1 deficiency; LR3 does not have a corresponding trial base. And the chronic-elevation safety concern is real, not precautionary boilerplate: sustained IGF-1 pathway activation is mechanistically connected to increased cancer risk and acromegalic features. That’s not a reason to avoid the compound as a research tool, but it firmly limits how aggressive a chronic-protocol investigator can be.

Differentiation within its niche is reasonable. Des(1-3)IGF-1 competes for some of the same in vitro applications, but LR3 is the dominant form in research catalogs and the more consistently cited analog across cell culture and rodent literature. For investigators specifically probing IGFBP-independent IGF-1R activation, it’s the practical default.

Honestly, we see this in the useful-but-not-urgent tier. Its bench value for IGF-1R biology, muscle research, and metabolic signaling programs is real and not overstated. But novelty is low, the evidence base for systemic investigational use is underdeveloped, and the safety constraints mean no major clinical program is going to be built on LR3 in its current form. Worth stocking for a serious GH-axis or muscle biology program. Dont expect it to anchor a novel research agenda on its own.

Novelty: 35
Mechanism promise: 40
In-category differentiation: 55
Evidence quality: 40
Translational signal: 35
Research bench value: 58

Rationale LR3’s IGFBP-reduction engineering is pharmacokinetically rational and it remains the dominant form for IGF-1R research requiring extended bioavailability, but the underlying mechanism is decades-old canonical PI3K/Akt/mTOR signaling with no novel target; formal human clinical data for the LR3 variant specifically is sparse, and chronic-elevation safety concerns actively constrain translational ambition.

Long Arg3 IGF-1 analog

A long-acting analog of IGF-1 with N-terminal extension and Arg3 substitution that reduces IGFBP binding and extends plasma half-life.

Abstract

IGF-1 LR3 (Long R3 IGF-1; CAS 946870-92-4; molecular weight 9111) is a recombinant analog of human IGF-1 with two structural modifications: a 13-residue N-terminal extension derived from the methionyl-N-terminal region of porcine GH, and substitution of arginine for glutamic acid at position 3. Both modifications reduce binding to IGF binding proteins (IGFBPs), which extends the plasma half-life and increases free bioavailable IGF-1 activity at IGF-1 receptors. The compound was originally developed for cell culture applications (mammalian cell growth media); research-grade availability supports investigational use. Pharmacokinetics: plasma half-life approximately 20 to 30 hours (versus 12 to 15 hours for native IGF-1). The compound is sold as a research chemical at concentrations typically 1 mg/mL. Investigational doses for performance applications range widely (20 to 100 micrograms per day) but the safety profile of long-term IGF-1 elevation is poorly characterized; chronic IGF-1 elevation is implicated in increased cancer risk and acromegalic features.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-087Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Long Arg3 IGF-1 analog

IGF-1 LR3

Abstract

Read the full monograph